|Bid||53.15 x 800|
|Ask||53.32 x 800|
|Day's Range||50.88 - 53.89|
|52 Week Range||33.40 - 85.30|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LivaNova PLC (NASDAQ:LIVN) shareholders are probably feeling a little disappointed, since its shares fell 5.8% to...
Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q3 results.Quarterly Results Earnings per share decreased 54.76% year over year to $0.38, which beat the estimate of $0.21.Revenue of $240,100,000 declined by 10.61% year over year, which beat the estimate of $218,550,000.Outlook The upcoming fiscal year's EPS expected to be between $1.15 and $1.35.The upcoming fiscal year's revenue expected to be between $900,000,000 and $1,008,000,000.How To Listen To The Conference Call Date: Oct 29, 2020View more earnings on LIVNTime: 08:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/ra82i375Technicals Company's 52-week high was at $85.3052-week low: $33.40Price action over last quarter: Up 0.73%Company Description U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.See more from Benzinga * Click here for options trades from Benzinga * Recap: Janus Henderson Q3 Earnings * Brunswick: Q3 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LivaNova (LIVN) delivered earnings and revenue surprises of 80.95% and 8.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?